Severe Eosinophilic Allergic Asthma Responsive to Mepolizumab After Failure of 2 Consecutive Biologics

J Investig Allergol Clin Immunol. 2019 Feb;29(1):79-81. doi: 10.18176/jiaci.0340.
No abstract available

Keywords: Anti-IL-5 antibodies; Biologics; Biomarkers; Phenotypes; Severe eosinophilic asthma.

Publication types

  • Case Reports

MeSH terms

  • Anti-Asthmatic Agents / therapeutic use*
  • Antibodies, Anti-Idiotypic / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Asthma / drug therapy*
  • Asthma / physiopathology
  • Biological Products / therapeutic use*
  • Eosinophilia / drug therapy*
  • Eosinophilia / physiopathology
  • Humans
  • Interleukin-13 / antagonists & inhibitors
  • Interleukin-5 / antagonists & inhibitors*
  • Male
  • Middle Aged
  • Treatment Failure

Substances

  • Anti-Asthmatic Agents
  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal, Humanized
  • Biological Products
  • IL13 protein, human
  • IL5 protein, human
  • Interleukin-13
  • Interleukin-5
  • anti-IgE antibodies
  • mepolizumab